Predicting the absolute risk of dying from colorectal cancer and from other causes using population-based cancer registry data

2011 ◽  
Vol 31 (5) ◽  
pp. 489-500 ◽  
Author(s):  
Minjung Lee ◽  
Kathleen A. Cronin ◽  
Mitchell H. Gail ◽  
Eric J. Feuer
Keyword(s):  
Colorectal Cancer ◽  
Cancer Registry ◽  
Absolute Risk ◽  
Population Based ◽  
Registry Data ◽  
Cancer Registry Data ◽  
The Absolute

scholarly journals German oncology certification system for colorectal cancer – relative survival rates of a single certified centre vs. national and international registry data

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Maximilian Richter ◽  
Lena Sonnow ◽  
Amir Mehdizadeh-Shrifi ◽  
Axel Richter ◽  
Rainer Koch ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
International Comparison ◽  
Cancer Registry ◽  
Survival Data ◽  
Survival Rates ◽  
Relative Survival ◽  
Registry Data ◽  
Cancer Registry Data ◽  
Colon And Rectal Cancer

Abstract Objectives To evaluate how the certification of specialised Oncology Centres in Germany affects the relative survival of patients with colorectal cancer (CRC) by means of national and international comparison. Methods Between 2007 and 2013, 675 patients with colorectal cancer, treated at the Hildesheim Hospital, an academic teaching hospital of the Hannover Medical School (MHH), were included. A follow-up of the entire patient group was performed until 2014. To obtain international data, a SEER-database search was done. The relative survival of 148,957 patients was compared to our data after 12, 36 and 60 months. For national survival data, we compared our rates with 41,988 patients of the Munich Cancer Registry (MCR). Results Relative survival at our institution tends to be higher in advanced tumour stages compared to national and international cancer registry data. Nationally we found only little variation in survival rates for low stages CRC (UICC I and II), colon, and rectal cancer. There were notable variations regarding relative survival rates for advanced CRC tumour stages (UICC IV). These variations were even more distinct for rectal cancer after 12, 36 and 60 months (Hildesheim Hospital: 89.9, 40.3, 30.1%; Munich Cancer Registry (MCR): 65.4, 28.7, 16.6%). The international comparison of CRC showed significantly higher relative survival rates for patients with advanced tumour stages after 12 months at our institution (77 vs. 54.9% for UICC IV; raw p<0.001). Conclusions Our findings suggest that patients with advanced tumour stages of CRC and especially rectal cancer benefit most from a multidisciplinary and guidelines-oriented treatment at Certified Oncology Centres. For a better evaluation of cancer treatment and improved national and international comparison, the creation of a centralised national cancer registry is necessary.

scholarly journals Cancer registry data based estimation of regional cancer incidence: application to breast and colorectal cancer in French administrative regions

1999 ◽  
Vol 53 (9) ◽  
pp. 558-564 ◽  
Author(s):  
M. Colonna ◽  
P. Grosclaude ◽  
J. Faivre ◽  
A. Revzani ◽  
P. Arveux ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Registry ◽  
Cancer Incidence ◽  
Registry Data ◽  
Cancer Registry Data

Population-based incidence estimates of uveal melanoma in Germany. Supplementing cancer registry data by case–control data

2006 ◽  
Vol 15 (2) ◽  
pp. 165-170 ◽  
Author(s):  
Andreas Stang ◽  
Andrea Schmidt-Pokrzywniak ◽  
Martin Lehnert ◽  
Donald M. Parkin ◽  
Jaques Ferlay ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Cancer Registry ◽  
Population Based ◽  
Case Control ◽  
Registry Data ◽  
Control Data ◽  
Cancer Registry Data

scholarly journals 365MO Exploring changes in glioblastoma treatment patterns in Europe and the USA with population-based cancer registry data

2020 ◽  
Vol 31 ◽  
pp. S398
Author(s):  
F. Giusti ◽  
M.D.C. Martos ◽  
S. Scoccianti ◽  
L. Neamtiu ◽  
G. Randi ◽  
...  
Keyword(s):  
Cancer Registry ◽  
Population Based ◽  
Treatment Patterns ◽  
Registry Data ◽  
Cancer Registry Data ◽  
The Usa

scholarly journals Differences in cancer survival by area-level socio-economic disadvantage: A population-based study using cancer registry data

PLoS ONE ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. e0228551 ◽  
Author(s):  
Nina Afshar ◽  
Dallas R. English ◽  
Tony Blakely ◽  
Vicky Thursfield ◽  
Helen Farrugia ◽  
...  
Keyword(s):  
Cancer Registry ◽  
Cancer Survival ◽  
Population Based ◽  
Registry Data ◽  
Economic Disadvantage ◽  
Population Based Study ◽  
Cancer Registry Data

Incidence patterns and survival of gynecological sarcoma in Germany: Analysis of population-based cancer registry data on 2106 women, 2009-2013.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e13058-e13058
Author(s):  
Klaus Pietzner ◽  
Nina Buttmann ◽  
Jalid Sehouli ◽  
Klaus Kraywinkel
Keyword(s):  
Cancer Registry ◽  
Survival Rates ◽  
Female Genital Tract ◽  
Relative Survival ◽  
Endometrial Stromal Sarcoma ◽  
Population Based ◽  
Registry Data ◽  
Uterine Leiomyosarcoma ◽  
Cancer Registry Data ◽  
Stromal Sarcoma

e13058 Background: Sarcoma of the female genital tract are rare tumors. They are described to be associated with a poor prognosis, when compared to gynecogical carcinoma. Aim of this study was to report incidence patterns and survival rates for gynecological sarcoma in Germany. Methods: Clinical data and survival rates for patients with gynecological sarcoma diagnosed in Germany between 2009 and 2013 were extracted from the German national centre for population-based cancer registry data. Incidence patterns and 5-year-relative survival rates were calculated. Results: A total of 2,106 gynecological sarcoma (GS) were eligible for analysis. The uterus was the most common site with 87.2% of all cases. The annual age-standardized incidence rate was 7.7 per 1 million women for all gynecological sarcoma. The median age at diagnosis was 59 years. The prognosis ranged according to site and subtype from a poor 5-year-relative survival of 47.6% (uterine leiomyosarcoma) to a very good 5-year-relative survival of 97.2% (endometrial stromal sarcoma). Conclusions: Despite the rareness of gynecological sarcoma, the size of the dataset allows a differentiation of subtypes according to morphology and site of origin. Clinically relevant differences in incidence and prognosis between subgroups were observed.

Sign in / Sign up

Export Citation Format

Share Document